PT  - JOURNAL ARTICLE
AU  - Usai, Carla
AU  - Gibbons, Joseph M.
AU  - Pade, Corinna
AU  - Li, Wenhao
AU  - Jacobs, Sabina R.M.
AU  - McKnight, Áine
AU  - Kennedy, Patrick T. F.
AU  - Gill, Upkar S.
TI  - The β-NGF/TrkA signalling pathway is associated with the production of anti- nucleoprotein IgG in convalescent COVID-19
AID  - 10.1101/2021.11.11.21266223
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.11.21266223
4099  - http://medrxiv.org/content/early/2021/11/11/2021.11.11.21266223.short
4100  - http://medrxiv.org/content/early/2021/11/11/2021.11.11.21266223.full
AB  - Background The presentation of SARS-CoV-2 infection varies from asymptomatic to severe COVID. Similarly, high variability in the presence, titre and duration of specific antibodies has been reported. While some host factors determining these differences, such as age and ethnicity have been identified, the underlying molecular mechanisms underpinning these differences remain poorly defined.Methods We analysed serum and PBMC from 17 subjects with a previous PCR confirmed SARS-CoV-2 infection and 10 unexposed volunteers following the first wave of the pandemic, in the UK. Anti-NP IgG and neutralising antibodies were measured, as well as a panel of infection and inflammation related cytokines. The virus-specific T cell response was determined by IFN-γ ELISPOT and flow cytometry after over-night incubation of PBMCs with pools of selected SARS-CoV-2 specific peptides.Results Seven of 17 convalescent subjects had undetectable levels of anti-NP IgG, and a positive correlation was shown between anti-NP IgG levels and the titre of neutralising antibodies (IC50). In contrast, a discrepancy was noted between antibody levels and T cell IFN-γ production by ELISpot following stimulation with specific peptides. Among the analysed cytokines, β-NGF and IL-1α levels were significantly different between anti-NP positive and negative subjects, and only β-NGF significantly correlated with anti-NP positivity. Interestingly, CD4+ T cells of anti-NP negative subjects expressed lower amounts of the β-NGF-specific receptor TrkA.Conclusions Our results suggest that the β-NGF/TrkA signalling pathway is associated with the production of anti-NP specific antibody in mild SARS-CoV-2 infection and the mechanistic regulation of this pathway in COVID-19 requires further investigation.Competing Interest StatementThis study was funded by Abbott Rapid Diagnostics as the sponsor. The authors declare that the research was conducted independent of the sponsor. The authors have no further commercial or financial relationships to disclose that could be construed as a potential conflict of interest. Sponsor s Primary Contact: Camilla Forssten, Abbott Rapid Diagnostics, Clearblue Innovation Centre, Priory Business Park, Bedford, MK44 3UP, UK, +44 7792 902 244, Fax +44 (0) 1234 759978, camilla.forssten@abbott.com.Funding StatementThis study was funded by Abbott Rapid Diagnostics as the sponsor. The authors declare that the research was conducted independent of the sponsor. The authors have no further commercial or financial relationships to disclose that could be construed as a potential conflict of interest. Sponsor s Primary Contact: Camilla Forssten, Abbott Rapid Diagnostics, Clearblue Innovation Centre, Priory Business Park, Bedford, MK44 3UP, UK, +44 7792 902 244, Fax +44 (0) 1234 759978, camilla.forssten@abbott.com.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:South Central - Berkshire Research Ethics Committee approved this work (ref: 20/SC/0191, ISRCTN60400862)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors